Clinical Trials Logo
  1. Home
  2. Oral Squamous Cell Carcinoma
  3. NCT05451303
  4. Details
NCT05451303 Clinical Trial

Detection of Oral and Throat Cancers Using OralViome Cancer Testing System

Oral Squamous Cell Carcinoma Clinical Trial

Official title:
Detection of Oral and Throat Cancers Using Saliva Metatranscriptomic Analysis

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05451303
Other study ID # V300
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 27, 2022
Est. completion date December 2025

Study information
Verified date December 2023
Source Viome
Contact Mory Mehrtash, MSc
Phone 425-300-6933
Email studies@viome.com
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

To evaluate the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic analysis. This study will recruit only at existing clinical sites and will NOT use any additional clinical sites.

Description:

This is an observational study evaluating the design, safety and efficacy of OralViome Cancer Testing system in the early detection of Oral and Throat Cancers using saliva metatranscriptomic. A total of 475 participants will be recruited, including 4 different cohorts: 1) cancer free patients, 2) patients with Oral Potentially Malignant Disease (OPMD), 3) patients with Oral Squamous Cell Carcinoma (OSCC), and 4) patients with OroPharyngeal Cancer (OPC). OSCC and OPC participants will be recruited from secondary care facilities, OPMD and cancer free participants will be recruited from primary care facilities. Participants will complete health questionnaires and collect saliva samples using at home/ in clinic kits provided by Viome. The duration of study participation will be 1 clinic visit for cancer free participants, and up to 1 year for those with OSCC/OPC/OPMD.

Recruitment information / eligibility
Status Recruiting
Enrollment 475
Est. completion date December 2025
Est. primary completion date December 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria for participants in OSCC or OPC cohorts - Participants must be diagnosed with oral squamous cell carcinoma (OSCC) and/or OroPharyngeal cancer (OPC) - Aged 18 years or older - Signed and dated informed consent prior to any study-specific procedures are performed - Willing and able to follow the study instructions, as described in the recruitment letter Exclusion Criteria for participants in OSCC or OPC cohorts - Pregnancy - Use of fertility enhancing medications - Active infection Inclusion Criteria for participants in OPMD cohorts - Any Oral Premalignant Disorder (OPMD) - Dysplasia - Hyperplasia - Leukoplakia - Erythroplasia - Lichenoid lesions - Actinic Keratosis - Lichenoid reaction - Aphthous ulcer/ Canker Sores - Gingival enlargement (side effect) - Lichen planus - Keratosis - Inflammatory reaction - Cheek bites - Aged =50 years OR aged 18 years or older with a history of tobacco use (see above) - Signed and dated informed consent prior to any study-specific procedures are performed - Willing and able to follow the study instructions, as described in the recruitment letter Exclusion Criteria for participants in OPMD cohorts - Pregnancy - Use of fertility enhancing medications - Active infection Inclusion Criteria for participants in cancer-free cohorts - Aged = 50 years OR aged 18 years or older with a history of tobacco use - Signed and dated informed consent prior to any study-specific procedures are performed - Willing and able to follow the study instructions, as described in the recruitment letter Exclusion criteria for participants in cancer-free cohorts - Pregnancy - Use of fertility enhancing medications - Active infection

Study Design

Related Conditions & MeSH terms

Intervention

Device:
• OralViome Cancer Testing System
The OralViome Cancer Testing System is intended for the screening of Oral Squamous Cell Carcinoma (OSCC) and Oropharyngeal cancer (OPC). The system consists of the OralViome Saliva Collection and Transport Kit, the Viome laboratory process for metatranscriptomics, and the Viome analytical software that detects an RNA expression signature within a saliva sample.

Locations
Country Name City State
United States NYMC New York New York

Sponsors (2)
Lead Sponsor Collaborator
Viome New York Medical College

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary The primary endpoint will be the detection or not of OSCC or OPC The test results will be compared against the definitive diagnosis by the physician. 1 year
See also
  Status Clinical Trial Phase
Recruiting NCT04543266 - Predicting Metastatic Oral Squamous Cell Carcinomas With Molecular Biomarkers Using Machine Learning
Recruiting NCT05024383 - Dissecting the Heterogeneity of Oral Cancer Pain N/A
Recruiting NCT06031337 - Salivary Expression of SOX7 in Oral Squamous Cell Carcinoma: Diagnostic Accuracy Study
Not yet recruiting NCT06174428 - Validity of Viome's Oral/Throat Cancer Test
Recruiting NCT05098119 - Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002) Phase 2
Recruiting NCT05069857 - Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients Phase 2
Not yet recruiting NCT03619304 - Assessment of Anti-cancerous Effect of Green, Roasted and Decaffeinated Coffee on Oral Squamous Cell Carcinoma Cell Line N/A
Active, not recruiting NCT01772706 - Laser Mucite ORL : Effectiveness of Laser Therapy for Mucositis Induced by a Radio-chemotherapy in Head and Neck Cancer N/A
Recruiting NCT05893888 - Safety and Efficacy Study of PRV211 in Subjects With Oral Squamous Cell Carcinoma Phase 1/Phase 2
Recruiting NCT05125055 - Neoadjuvant Anti-PD-1 and TP Versus TPF on Pathological Response in OSCC Phase 2/Phase 3
Not yet recruiting NCT06055868 - People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Not yet recruiting NCT06130007 - A Prospective, Single-arm Phase II Clinical Trial of Tislelizumab Combined With Platinum Doublet Neoadjuvant Therapy to Improve Mandibular Preservation in Resectable Locally Advanced Oral Squamous Cell Carcinoma. Phase 2
Recruiting NCT05798793 - Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma Phase 3
Recruiting NCT02739204 - Concurrent Radiotherapy and/or Cisplatin With or Without Celecoxib in Patients With Primary Oral Squamous Cell Carcinoma Phase 2
Completed NCT05708209 - The Long Non Coding MALAT1 as a Potential Salivary Diagnostic Biomarker in Oral Squamous Cell Carcinoma Through Targeting mi RNA 124
Recruiting NCT05862168 - Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial Phase 2
Recruiting NCT05902455 - Differential Mobility Spectrometry (DMS) Based Oral Tumor Analysis
Not yet recruiting NCT05803915 - Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy Phase 2
Recruiting NCT05791149 - Epigenetic Biomarkers in the Saliva for the Diagnosis of Squamous Cells Carcinoma of the Oral Cavity N/A
Active, not recruiting NCT04649476 - Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma Phase 2